1 We compared effects on motor function of four peptides belonging to the dynorphin familydynorphin-(1-17) (DYN-(1-17) ), dynorphin-(1-13) (DYN-(1-13)), dynorphin-(1-8) ) and a-neo-endorphin (aNE). 2 After intrathecal administration, each of these peptides produced dose-related, flaccid, hindlimb paralysis, with the order of potency being DYN-(1-17) > DYN-(1-13) > aNE DYN-(1-8). 3 This motor dysfunction was not reversed or blocked by the opiate receptor antagonist naloxone and was not produced by a variety of other K-selective agonists. 4 However, paralysis was produced by des-Tyr-dynorphin (DYN-(2-17)), which does not act at the opioid receptor. 5 Taken together, the present studies show that dynorphin-related peptides, uniquely amongst opioids, produce motor dysfunction, an action which does not appear to be mediated by opioid receptors.
Introduction
Dynorphin is a recently recognized endogenous opioid peptide which is found widely distributed within the central nervous system, in addition to its localization in the hypothalamic-pituitary axis (Gramsch, Hoilt, Pasi, Mehraein & Herz, 1982; Watson, Khachaturian, Akil, Coy & Goldstein, 1982 ). It appears, moreover, to be an endogenous ligand for the ic-opioid receptor (Huidobro-Toro, Yoshimura, Lee, Loh & Way, 1981; Chavkin, James & Goldstein, 1982) . Dynorphin has a variety of physiological effects, some of which are opiate receptor mediated and others which probably are not (Walker, Moises, Coy, Baldrighi & Akil, 1982) . We have recently found that dynorphin-(1-17) ) induces dose-related, partially reversible, hindlimb paralysis following intrathecal administration in the rat, an action not produced by 6-or gi-selective synthetic enkephalins or by P-endorphin (Faden & Jacobs, 1983) . Thus, the paralysis produced by dynorphin appears to be relatively unique amongst opioids. It is now known that there exists a family of dynorphin-related peptides, each probably derived from the same pro-hormone, which have different concentrations within the central nervous system and different affinities for the opiate receptor (Kakidani, Furutani, Takahashi, Noda, Morimoto, Hirose, Asai, Inayama, Nakanishi & Numa, 1982; Weber, Evans & Barchas, 1982) . In the present studies we compared the effects of DYN-(1-17), dynorphin-(1-13) (DYN-(1-13)), dynorphin-(1-8) ) and x-neo-endorphin (cxNE) on motor dysfunction in the hindlimbs following intrathecal administration in the rat. In addition, we have examined the potential role of opioid receptors in mediating the motor dysfunction by studying the ability of naloxone to modify this action of dynorphin, the ability of other K-receptor agonists to produce this paralysis, and finally of the ability of des-Tyr-dynorphin (DYN-(2-17)) to simulate this effect.
Methods
Male Sprague-Dawley rats (300 g) were anaesthetized with ketamine hydrochloride (50 mg kg- ', i.m.) and sodium pentobarbitone (25 mgkg-1, i.p.).
Polyethylene tubing (PE 10) was placed in the spinal subarachnoid space and threaded to the level of the lumbar enlargement, using a modification (Faden & Jacobs, 1983) of the method of Yaksh & Rudy (1976) . Twenty-four hours later, drugs were infused in a total volume of 23 pl (artificial CSF) over 2 min, an infusion method which we have previously shown produces no motor changes in saline-treated animals and no forelimb weakness in dynorphin-treated animals (Faden & Jacobs, 1983 OL_ Hindlimb neurological function was evaluated over a 48 h period after infusion. Neurological function was graded using a 4-point ordinal scale as follows: 0 = paraplegia; 1 = severe paraparesis; 2 = mild paraparesis with ability to walk; and 3 = normal motor function. Differences in neurological function among the groups were compared utilizing Mann-Whitney U-Tests.
Results
As we have previously shown for DYN-(1 -17), infusion with DYN-(1-13) produced dose-related, flaccid, hindlimb paralysis appearing within the first 10 min post-infusion (Figure la) . This motor dysfunction was absent at 10rnmol, mild with 30nmol and moderately severe with doses of 50 and 100 nmol (Figure la) . In contrast, DYN-(1-17) at a dose of 30 nmol produced complete paralysis in eight of nine animals at 15 min post-injection (Figure lb) . produced no effects at 50 nmol and mild transitory changes at 100 nmol (Figure lb) . Similarly, aNE produced no change at 30 nmol and minimal dose-related changes at 50 and 100 nmol (Figure lb) . (Table   1) . Naloxone doses utilized were quite high: 100 ytg i.t., and up to 10 -20 mg kg-1 i.v. In contrast to the effects of dynorphin peptides, hindlimb paralysis was not produced by other K-selective agonists administered i.t., even up to doses of 100 nmol (Table 2) . Moreover, DYN-(2-17) (des-Tyr-dynorphin), a peptide which is not active at the opiate receptor but which has physiological actions (Walker etal., 1982) , produced hindlimb paralysis which was similar to that resulting from DYN-(1-17) (Table 3) . Although not quite as potent in this regard as , the potency of DYN-(2-17) in eliciting paralysis exceeded that of the other dynorphin-peptides (compare Table 3 and Figure lb) .
Discussion
Several groups have now shown that dynorphin produces hindlimb paralysis following intrathecal administration in the rat (Hermann, 1982; Przewlocki, Shearman & Herz, 1983; Faden & Jacobs, 1983) . Hermann (1982) observed paralysis at doses above 10 nmol and indicated that this motor dysfunction was 'irreversible' at doses above 20 nmol. Przewlocki et al. (1983) found motor paralysis in four out of six rats given 4.7 nmol dynorphin, and all rats given 23.3 or 46.6 nmol, but not rats given up to 81.4 nmol cxNE or up to 51 nmol DYN-(1-8); they did not mention the duration of the paralysis produced by dynorphin. Neither of these groups quantified the dynorphininduced motor dysfunction. We have shown (Faden & Jacobs, 1983 ) that dynorphin-induced paralysis is dose-related and, largely, spontaneously reversible over a 48 h period; motor dysfunction was scored by several observers using a 4-point ordinal scale. At high doses (50 nmol), however, one-third of the animals developed paralysis that was non-reversible.
The present studies demonstrate that dynorphininduced paralysis is produced by other peptides of the dynorphin family, with the order of potency being DYN-(1-17) > DYN-(1 13) > aNE -~DYN-(1-8) (Figure 1 ). Since dynorphin-related peptides appear to be endogenous ligands for the K-receptor (Huidobro-Toro et al., 1981; Chavkin et al., 1982) , and the Kc-receptor appears to be the predominant type of opioid receptor in the spinal cord of the rat Table 3 Comparison of intrathecal infusion of dynorphin-(1-17) (DYN-(1-17) ) and dynorphin-(2-17) (DYN-(2-17)) on hindlimb function in the ratt 
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(100 nmol) mOOXXX (Traynor, Kelley & Rance, 1982) , the above observations are consistent with the conclusion that dynorphin-induced paralysis may result from actions mediated by the K-receptor. On the other hand, DYN-(2-17), which does not act at the opiate receptor (Chavkin & Goldstein, 1981) , has potent physiological activity (Walker et aL, 1982) . To distinguish these alternative mechanisms by which dynorphin might exert its paralytic effects, three parallel studies were performed: (1) to examine whether dynorphin paralysis could be modified by the opiate-receptor antagonist naloxone; (2) to determine whether other Kc-selective agonists produced such paralysis; and (3) to observe whether des-Tyrdynorphin could induce motor dysfunction. Dynorphin-induced motor dysfunction was not modified by intravenous naloxone, administered either as pretreatment or post-treatment, up to doses of 10 -20 mg kg-1 (Table 1) . Similarly, naloxone administered intrathecally as pretreatment at a dose of 100 fig failed to modify this dynorphin response.
These findings are consistent with those of Hermann (1982) who observed that dynorphin paralysis was not reversed by naloxone up to a dose of 32 mgkg-' s.c. In contrast, Przewlocki et al. (1983) found that hindlimb paralysis produced by dynorphin at a dose of 4.7 nmol was blocked by naloxone pretreatment at a dose of 10 mg kg-I but not at 1 mg kg-1. However, neither Hermann nor we observed significant motor dysfunction with doses at or below 10 nmol.
Other K-selective opioid agonists (bremazocine, MRZ or U-50488H) failed to produce any motor dysfunction when administered intrathecally at doses up to 100 nmol (Table 2 ). In contrast, DYN-(2-17) caused hindlimb paralysis, with a potency between that of DYN-(1-17) and DYN-(1-13) (Table 3, Figure 1 ). Paralysis after DYN-(2-17) was doserelated and persisted up to 48 h after the highest dose (50 nmol); 2 of 10 such animals showed severe irreversible paralysis. Similarly, Przewlocki et al. (1983) observed transitory motor dysfunction after relatively high dose infusions (35.1 nmol) of DYN-(2-13). Taken together, these findings strongly support the conclusion that the dynorphin-induced paralysis does not result from actions at opioid receptors. Rather, this motor dysfunction appears to reflect a non-opiate receptor mediated, pharmacological action of this class of peptides, similar to other effects, including posturing and electroencephalographic changes, which have recently been observed after intracerebroventricular administration (Walker etal., 1982 
